share_log

Earnings Call Summary | Icecure Medical(ICCM.US) Q4 2023 Earnings Conference

moomoo AI ·  Apr 3 13:26  · Conference Call

The following is a summary of the IceCure Medical Ltd. (ICCM) Q4 2023 Earnings Call Transcript:

Financial Performance:

  • IceCure's revenues saw a year-on-year increase of 26% to $3 million from sales of ProSense systems and disposables.

  • Gross profit for the year was $1.3 million, with a gross margin of 40%, a decrease from the previous year's 47% due to a decrease in revenue recognition from the Terumo distribution agreement.

  • The company's net loss for the year decreased by 14% to $14.7 million or $0.32 per share.

Business Progress:

  • Following the completion of the ICE3 study, IceCure plans to submit study data and real-world data to the FDA.

  • The company is preparing for the commercial launch of ProSense for early-stage breast cancer in the U.S.

  • IceCure is working on their XSense cryoablation system and expanding their distribution networks in the United States, Europe, India, and Brazil, expecting accelerated growth of their ProSense system.

More details: Icecure Medical IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment